These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2108882)

  • 21. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
    Dowsett M; Mehta A; Mansi J; Smith IE
    Br J Cancer; 1990 Nov; 62(5):834-7. PubMed ID: 2123115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P; Jocham D
    Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteinizing hormone releasing hormone agonists: the US experience.
    Nabors W; Crawford ED
    J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
    Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
    Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
    Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
    Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
    Kienle E; Lübben G
    Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
    Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leuprorelin acetate granulomas: case reports and review of the literature.
    Yasukawa K; Sawamura D; Sugawara H; Kato N
    Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.
    Glode LM; Smith JA
    J Urol; 1987 Jan; 137(1):57-60. PubMed ID: 3098990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulation study of leuprorelin acetate to improve clinical performance.
    Toguchi H
    Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.